On Wednesday, Biocon stock slipped 0.55 per cent to settle at Rs 364.55 apiece on the BSE.

Biocon has completed the acquisition of the remaining equity shares of its unlisted subsidiary Biocon Biologics from Mylan ...

Pharma stocks rise as Cipla faces supply issues, Zydus gains FDA approval, and Biocon secures funding through a QIP.

Biotech firm Biocon on Thursday said it has raised Rs 4,150 crore through a Qualified Institutions Placement (QIP) process.

Indian biopharmaceutical company Biocon said on Saturday it would fully integrate its biosimilar unit Biocon Biologics as a wholly owned subsidiary, consolidating Biocon’s biosimilars and generics ...

Biocon said the proceeds would be primarily used to meet the cash consideration payable to Mylan Inc, now Viatris, for the acquisition of its shareholding in Biocon Biologics Ltd.

Biocon Ltd is quoting at Rs 383.95, up 1.31% on the day as on 12:49 IST on the NSE. The stock is down 2.48% in last one year as compared to a 11% jump in NIFTY and a 1.13% jump in the Nifty Pharma ...

Biocon Ltd. Quarterly balance sheet by MarketWatch. View all BIOCON assets, cash, debt, liabilities, shareholder equity and investments.

Biocon Ltd. Annual cash flow by MarketWatch. View BIOCON net cash flow, operating cash flow, operating expenses and cash dividends.

Indian equity benchmarks end flat in thin year-end trade; IT losses weigh India's equity benchmarks closed little changed on Wednesday in a subdued session marked by thin year-end volumes, with losses ...